Application of boronated anti-CEA immunoliposome to tumour cell growth inhibition in in vitro boron neutron capture therapy model

Br J Cancer. 1991 Apr;63(4):522-6. doi: 10.1038/bjc.1991.124.

Abstract

An immunoliposome containing a 10B-compound has been examined as a selective drug delivery system in boron neutron-capture therapy. Liposomes, conjugated with monoclonal antibodies specific for carcinoembryonic antigen (CEA) were shown to bind selectively to cells bearing CEA on their surface. The immunoliposomes attached to tumour cells suppressed growth in vitro upon thermal neutron irradiation and suppression was dependent upon the concentration of the 10B-compound in the liposomes and on the density of antibody conjugated to the liposomes. The results suggest that immunoliposomes containing the 10B-compound could act as a selective and efficient carrier of 10B atoms to target tumour cells in boron neutron-capture therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / pharmacology
  • Boron / administration & dosage*
  • Carcinoembryonic Antigen / immunology*
  • Cell Division / drug effects
  • Cell Division / radiation effects
  • Gamma Rays
  • Humans
  • Isotopes
  • Liposomes / pharmacology
  • Neutrons / therapeutic use*
  • Pancreatic Neoplasms / immunology
  • Pancreatic Neoplasms / pathology
  • Pancreatic Neoplasms / radiotherapy*

Substances

  • Antibodies, Monoclonal
  • Carcinoembryonic Antigen
  • Isotopes
  • Liposomes
  • Boron